Integer (NYSE:ITGR) PT Raised to $139.00

Integer (NYSE:ITGR - Get Free Report) had its price objective upped by research analysts at KeyCorp from $123.00 to $139.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has an "overweight" rating on the medical equipment provider's stock. KeyCorp's price objective indicates a potential upside of 16.82% from the stock's previous close.

Several other research analysts have also recently issued reports on the company. CL King started coverage on Integer in a research note on Thursday, March 14th. They issued a "buy" rating and a $137.00 price objective for the company. Benchmark raised their price target on shares of Integer from $105.00 to $130.00 and gave the stock a "buy" rating in a research report on Thursday, March 28th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $117.60.

Integer Stock Up 3.1 %

Shares of NYSE:ITGR traded up $3.59 on Tuesday, reaching $118.99. The company had a trading volume of 416,797 shares, compared to its average volume of 294,149. The company has a current ratio of 2.80, a quick ratio of 1.71 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $3.97 billion, a PE ratio of 42.89, a PEG ratio of 1.45 and a beta of 1.10. Integer has a 52-week low of $69.40 and a 52-week high of $119.00. The firm's 50 day simple moving average is $109.39 and its 200-day simple moving average is $96.30.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings data on Thursday, February 15th. The medical equipment provider reported $1.39 EPS for the quarter, topping the consensus estimate of $1.34 by $0.05. The firm had revenue of $413.15 million during the quarter, compared to analyst estimates of $409.04 million. Integer had a net margin of 5.68% and a return on equity of 10.80%. Integer's revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.11 EPS. As a group, analysts expect that Integer will post 5.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integer

A number of institutional investors have recently modified their holdings of the company. Handelsbanken Fonder AB boosted its holdings in Integer by 1.7% in the fourth quarter. Handelsbanken Fonder AB now owns 5,837 shares of the medical equipment provider's stock valued at $578,000 after purchasing an additional 100 shares during the period. Cetera Advisor Networks LLC boosted its holdings in Integer by 2.4% in the fourth quarter. Cetera Advisor Networks LLC now owns 4,611 shares of the medical equipment provider's stock valued at $457,000 after purchasing an additional 106 shares during the period. Cornercap Investment Counsel Inc. lifted its holdings in Integer by 1.0% during the 4th quarter. Cornercap Investment Counsel Inc. now owns 12,014 shares of the medical equipment provider's stock worth $1,190,000 after buying an additional 121 shares during the last quarter. Arizona State Retirement System lifted its holdings in Integer by 1.4% during the 3rd quarter. Arizona State Retirement System now owns 9,474 shares of the medical equipment provider's stock worth $743,000 after buying an additional 131 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in Integer by 10.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider's stock worth $141,000 after buying an additional 132 shares during the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.